| |
|
Novartis' cancer drug not patentable, may challenge verdict
|
|
Published on :
Sunday, July 05, 2009 |
|
The Intellectual Property Appellate Board (IPAB) has said that Novartis’ cancer drug Glivec (Imatinib Mesylate) is not patentable in the beta crystalline form. After the Patent Office rejected Novartis’ patent application on Glivec in 2006, Novartis filed multiple writs in the Madras High Court contesting the rejection of its patent application and certain constitutional parameters that contributed to the rejection. |
|
|
|
|
A deadly organ donor system: Needs a market
|
|
Published on :
Sunday, July 05, 2009 |
|
The same economic system that generally makes good healthcare available to all, does price of certain products and services high enough that only the wealthy can afford them. It isn’t news that the world’s finest surgeon commands a high fee, or that the latest “miracle’’ drugs tend to be expensive, or that billionaires can afford things that mere mortals can’t. The result of our misguided altruism-only organ donation system is much the same: too few organs and too much death, writes Jeff Jacoby in The Boston Globe. |
|
|
|
|
Attack on Patents Hurts the Poor
|
|
Published on :
Wednesday, April 09, 2008 |
|
The attack on patents is not a defence of patients or the poor. It is diverting attention from what really matters: infrastructure, doctors and nurses. Prosperity is the key to those services and intellectual property is one of the keys to prosperity. The "patients not patents" campaign has a simplistic appeal but will only make things worse for the poor, as well as distracting attention from the real causes of ill health: poverty and corruption, writes Alec van Gelder & Franklin Cudjoe in the Business Daily Africa |
|
|
|
|
Why MNCs dont bring blockbuster drugs into India
|
|
Published on :
Friday, February 29, 2008 |
|
Reasons: Lack of patent recognition, delay in approvals, litigation woes
India had access to only about 30 per cent of the 105 global blockbusters, says Mr Graham Lewis, Vice-President (Europe) of IMS Health. In the pre-product patent period, India was a “copy market” (where local companies made similar versions of original innovative medicines). But even in the post-product patent period, multinational companies do not seem to have the confidence to bring in their blockbusters, as approvals are not happening fast enough, writes P.T. Jyothi Datta in the Hindu Business Line |
|
|
|
|
A dose of reality on pharma intellectual property
|
|
Published on :
Tuesday, September 18, 2007 |
|
Health officials from all over Asia gathered at a World Health Organization (WHO) meeting in Manila to discuss an issue that is rarely out of the papers in the Philippines: how do patents affect drug prices, and what can be done to ensure that the poor can get access to high quality medicines?, writes Philip Stevens. |
|
|
|
|
Civil Society responds to the WHO’s working group on innovation and health
|
|
Published on :
Tuesday, September 11, 2007 |
|
In 2006, the World Health Organization issued a report which claimed that too few drugs are developed for ‘neglected’ tropical diseases that especially affect poor countries, and that the international patent system prevents drugs from getting to the neediest. |
|
|
|
|
Patients victims of politics
|
|
Published on :
Tuesday, March 20, 2007 |
|
Politicians find it very convenient to adopt a tactics of bashing MNCs, and divert attention away from the illness that affects Indian health care system. India did not recognise product patent in medicines for over three decades, 97% of the medicines in the market is believed to be off-patent. Yet, it is estimated that 60-70% of Indians never access any modern health care system. Barun Mitra looks at how politics affects health care in India. |
|
|
|